For people living with locally advanced head and neck squamous cell carcinoma, the journey of treatment can feel uncertain. One of the biggest questions patients and doctors face is whether a specific treatment will actually shrink or eliminate the cancer before surgery or radiation begins. This type of early treatment is called neoadjuvant immunotherapy. Because every patient's body reacts differently to these drugs, finding ways to predict success is vital for providing the best care possible.
A large review of 26 different studies looked at 980 patients to find clues about what makes some people respond better to immunotherapy than others. The researchers focused on three specific markers: a score called CPS (which measures how many immune cells are attacking the tumor), the presence of the human papillomavirus (HPV), and the amount of CD4+ lymphocytes (a type of white blood cell that helps the immune system).
The findings showed a clear link between these markers and how well the treatment worked. Specifically, patients with higher CPS scores—especially those above 5, 10, 20, 30, 40, or 50—showed significantly better response rates than those with lower scores. Additionally, patients who tested positive for HPV were more than twice as likely to show a strong response to the treatment compared to those who were HPV negative. The study also found that having more CD4+ white blood cells in the tumor area was linked to a better response.
While these results are encouraging, it is important to keep things in perspective. This was a meta-analysis, which means it combined data from many different studies to see a bigger picture. While the links between these markers and treatment success were consistent across the data, they do not prove that one causes the other. Furthermore, because this was an analysis of existing data rather than a single new clinical trial, we cannot yet say for certain how these markers will change daily medical practice. For patients right now, this means that while these markers are promising tools for doctors to use in the future, they are not yet a definitive rulebook for choosing treatment. More clinical studies are needed to confirm these findings and turn them into standard guidelines. For now, these results offer hope that medicine is moving toward more personalized care, where a patient's unique biology helps guide their specific path forward.
